



## SUPPLEMENTARY INFORMATION

**Supplementary Table S1.** Values of the hematological parameters in HNSCC patients prior to induction chemotherapy (ICT) treatment.


	<b>Hemoglobin</b>	<b>Leucocytes</b>	<b>Neutrophils</b>	<b>Lymphocytes</b>	<b>Platelets</b>	<b>NLR</b>
	<b>(gr/dl)</b>	<b>(cells/mm<sup>3</sup>)</b>	<b>(cells/mm<sup>3</sup>)</b>	<b>(cells/mm<sup>3</sup>)</b>	<b>(cells/mm<sup>3</sup>)</b>	
<b>Mean</b>	14.3	8845.57	5847.21	2079.67	247183.33	3.69
<b>Median</b>	14.5	8400	5450	1920	240500	2.64
<b>SD</b>	1.64	1875.87	1946.26	880.25	66343.86	2.98
<b>Minimum</b>	10.6	6000	2880	500	147000	0.58
<b>Maximum</b>	17.6	13250	10700	4970	489000	17.4




**Supplementary Figure S1.** Disease-specific (A) and overall (B) survival curves categorized according to the response to induction chemotherapy (ICT).



**Supplementary Figure S2.** ROC curves used to calculate the optimal cut-off values for the neutrophil-to-lymphocyte ratio (NLR) in relation to the response to induction chemotherapy (A), and patient survival (B). The optimal values calculated are shown.



**Supplementary Figure S3.** Disease-specific survival curves categorized according to neutrophil-to-lymphocyte ratio (NLR; A, B), PD-L1 composite proportion score (CPS; C, D), and CD8+ TIL density (E, F), in the subsets of patients treated with chemoradiotherapy or surgery.



**Supplementary Figure S4.** Disease-specific (A) and overall survival curves categorized according to the type of immune tumor microenvironment.